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Abstract
Gemcitabine is an antimetabolite drug with proven anti-
tumor activity and tolerability in metastatic breast can-
cer. In a total of nine studies, gemcitabine monotherapy
has reached response rates of up to 37% in the first-line
setting, 26% in the second-line setting, and 18% or better
in the third-line setting. Gemcitabine is an excellent
choice for combination therapy by its unique mechanism
of action and favorable toxicity profile, thus limiting the
risk of pretreatment-related drug resistance and overlap-
ping toxicity, and by its potential for synergistic interac-
tion with some combination partners as indicated in pre-
clinical studies. Numerous phase II clinical studies have
combined gemcitabine with other active agents such as
the taxanes, vinorelbine, vindesine, cisplatin, 5-fluoro-
uracil, as well as anthracyclines across various regimens
and conditions of pretreatment. Most of these two-drug
combinations have consistently demonstrated higher ef-
ficacy than either single agent, particularly in pretreated
patients. Even higher efficacy has been obtained with tri-
ple-drug regimens including gemcitabine, anthracy-
clines (epirubicin or doxorubicin), and paclitaxel; these
regimens have yielded overall response rates of 58–92%
as first-line treatment. In view of these results, gemcita-
bine may be regarded as a valuable alternative to the pal-
liative treatment of metastatic breast cancer, and an
excellent option for the development of effective combi-
nation treatment not only in first-line therapy, but also
for intensively pretreated patients previously exposed to
anthracyclines and/or the taxanes.
Copyright © 2003 S. Karger AG, Basel
Introduction
Metastatic breast cancer treatment is characterized by
the availability of multiple treatment options made possi-
ble by active single agents and their combinations, the
effectiveness of which is not limited to first- and second-
line settings.
Single-agent therapy in chemonaive patients has
achieved overall response rates of 25–55%, which may be
improved further to 35–80% with combination therapy
[1]. Median durations of response have been in the range
of 6–12 months in most studies. In randomized phase III
trials, front-line monotherapy has attained median pro-
gression-free survival times of 4–8 months and median
survival times of 14–22 months [2–5]. As second-line
treatment, single agents have produced response rates of
20–40% and response durations of 2–8 months [1].
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Despite progress in the development and understand-
ing of new drugs, clearly defined steps toward improved
survival in patients with advanced breast cancer have not
been delineated recently. Strategies are confounded by the
increasing exposure of patients to chemotherapy in the
adjuvant setting. Nevertheless, two general strategies are
apparent and should be followed: (1) improving treatment
efficacy by exploring new drugs and drug combinations,
and (2) ensuring that efficacy is improved with the lowest
cost to quality of life.
Gemcitabine (2)2)-difluorodeoxycytidine, dFdC) is a
novel nucleoside antimetabolite that has proven systemic
and preclinical antitumor activity in a variety of human
solid tumors, including pancreatic, non-small-cell lung,
bladder, ovarian, as well as breast tumors [6–8]. The par-
ent compound is phosphorylated intracellularly by deoxy-
cytidine kinase to the active metabolites, gemcitabine
diphosphate, and triphosphate [9]. Gemcitabine triphos-
phate competes with deoxycytidine triphosphate (dCTP)
for incorporation into DNA as a fraudulent base, which
results in masked chain termination and inhibition of fur-
ther DNA synthesis. Gemcitabine diphosphate inhibits
ribonucleotide reductase, an enzyme responsible for cata-
lyzing dCTP. The subsequent decrease in dCTP poten-
tiates the incorporation of gemcitabine triphosphate into
DNA, and enhances phosphorylation of gemcitabine
since there is less dCTP to inhibit deoxycytidine kinase
[10, 11]. These self-potentiating mechanisms prolong the
retention of active gemcitabine in tumor cells.
Among the multitude of available agents, gemcitabine
stands out because of its good tolerability and side-effect
profile [12]. The mild toxicity of gemcitabine certainly
favors its combination with other antitumor drugs. In
addition, the novel mechanism of action of this agent [11]
reduces the possibility of pretreatment-associated drug
resistance.
While gemcitabine has already demonstrated clinical
efficacy as a single agent in breast cancer [13–21], knowl-
edge regarding its treatment profile in combination thera-
py against this tumor is only recently emerging. On this
basis, this review has evaluated the clinical applicability
and efficacy of gemcitabine-based combination therapy
in metastatic breast cancer.
Methods
The MEDLINE database was searched for publications related to
the use of gemcitabine in breast cancer [22]. In addition to full publi-
cations, abstracts presented at the meetings of the American Society
of Clinical Oncology (ASCO), the European Cancer Conference
(ECCO), and the San Antonio Breast Cancer Meeting were also
included. The present review considered only those publications that
included at least 19 evaluable patients. Phase I data were not
included (except in cases where phase II results were not available),
and phase III studies have not yet been reported. Because survival
data are typically not reported in phase II trials, we did not include
these data in this review; however, this review did include time to
disease progression whenever reported, as this endpoint is relevant to
these studies.
Results
Single-Agent Gemcitabine
Nine studies are available that provide an initial
assessment of the single-agent activity and tolerability of
gemcitabine in advanced breast cancer [13–21] (table 1).
Comparability among the studies is limited by different
gemcitabine regimens and conditions of pretreatment.
The most frequently applied regimens were doses of 1,000
or 1,200 mg/m2 administered over 4-week cycles.
Gemcitabine monotherapy has produced overall re-
sponse rates of up to 37% in the first-line setting [13–15],
26% in the second-line setting [15, 17], and 13% in the
third-line setting [17]. In studies limited to second- or
third-line therapy after anthracycline and/or taxane expo-
sure, response rates have reached 29% [16, 17, 19].
Median time to progression has varied from 2 to 6 months
[13–17, 20, 21].
The considerable difference between response rates
produced by the first-line studies of Blackstein and
Possinger (37 vs. 14%) remains unclear [13, 14]. The
lower gemcitabine dose intensity in the Possinger study
(994 mg/m2) compared to that of the Blackstein study
(1,053 mg/m2) can hardly be claimed as a reason for the
lower treatment activity, as the remission rate in the Car-
michael study, which reported an even lower dose intensi-
ty (775 mg/m2), was nearly twice as high (25%). More-
over, the ratios of patients with estrogen receptor positivi-
ty and prior adjuvant treatment were lower, and therefore
more favorable, in the Possinger study. It should be
pointed out, however, that the percentage of patients
achieving stable disease was comparatively higher in the
Possinger study (57 vs. 49%). Accordingly, the inhibition
of tumor progression (stable disease + overall response)
did not differ greatly between the studies (57 + 14% for
Possinger and 49 + 37% for Blackstein).
In one study in which all patients had failed both
anthracycline- and taxane-based chemotherapy, there
were no responders, although 6 of the 21 evaluable
patients achieved stable disease [21]. The heavy pretreat-
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Table 1. Gemcitabine monotherapy
Reference
(first author)
N/Resp
eval
Prior chemotherapy Study dose
mg/m2
Median
TTP, months
ORR, % WHO grade 3 or 4 toxicitya, n or % of patients
Blackstein
[13]
39/35 1st-line 39 pts
Adjuvant 19 pts
1,200 d1, 8,
15 q 4 wks
5.1 37
(median RD = 8.8 mos)
G3: neutropenia (9), thrombocytopenia (2),
ALT (2), cutaneous (1), nausea/vomiting (4);
G4: pulmonary (1), infection (1)
Possinger
[14]
42/42 1st-line 42 pts
Adjuvant 10 pts
1,000 d1, 8,
15 q 4 wks
3.8 14
(median RD = 5.6)
G3/4: nausea/vomiting (6), ALP (1), ALT (8),
neutropenia (8), thrombocytopenia (2);
G3 only: ALP (1), AST (2)
Carmichael
[15] 
44/40 1st-line 14 pts
2nd-line 19 pts
Anthracyclines 17 pts
Adjuvant 7 pts
800 d1, 8,
15 q 4 wks
2.1b 25.0
(median RD = 13.5 mos)
1st-line: 36 (5/14)
2nd-line: 26 (5/19)
G3/4: neutropenia (30%), leukopenia (9%);
anemia and thrombocytopenia mininal;
AST (9%), nausea/vomiting (27%);
G4 only: infection (2%);
G3 only: allergic, rash, cardiac function, alopecia,
altered consiousness (2% for each)
Valerio
[16]
26/22 2nd- or 3rd-line 26 pts
Anthracycline, taxane
1,000 d1, 8,
15 q 4 wks
NA 23 No grade 3 or 4 toxicity was reported;
main toxicities were influenza-like syndrome
with fever (10) and fatigue (8)
Brodowicz
[17]
25/25 2nd-line 9 pts
3rd-line 16 pts
Anthracyclines 25 pts
Taxanes 6 pts
1,250 d1, 8,
15 q 4 wks
3.6
2nd-line: 5.1
3rd-line: 3.5
16
2nd-line: 22 (2/9)
3rd-line: 13 (2/16)
G3: thrombocytopenia (1)
G4: thrombocytopenia (4)
Gerson
[18]
19/19 1st-line 2 pts
2nd-line 6 pts
3rd-line 6 pts
13rd-line 5 pts
1,250 d1, 8,
15 q 4 wks
NA 42
(median RD = 8.5 mos)
Hematologic side effects (9; grade not reported),
grade 2/3 thrombocytopenia (5); nausea, vomiting,
dysuria, alopecia (2 each; grade not reported)
Spielmann
[19]
47/41 2nd-line 32 pts
3rd-line 15 pts
(61 anthracycline-
or anthracenedione-
based CT)
Adjuvant 11 pts
1,200 d1, 8,
15 q 4 wks
NA 29
(median RD = 8.1 mos)
G3: neutropenia (13), thrombocytopenia (3),
nausea/vomiting (4), cutaneous (1);
G4: neutropenia (1)
Schmid
[20]
20/20 1st-line 4 pts
2nd-line 5 pts
63rd-line 11 pts
Adjuvant 10 pts
Anthracyclines 15 pts
250, 6-hour
infusion, d1, 8,
15 q 4 wks
6.3 25
63rd-line: 18 (2/11)
G3 only: leukopenia (4% of cycles); AST,
ALT (10% of cycles for each); GGT (8% of cycles),
nausea/vomiting (4% of cycles), alopecia
(3% of cycles)
Smorenburg
[21]
23/21 2nd-line 3 pts
63rd-line 20 pts
Failed anthracycline-
and taxane-based CT
Adjuvant 11 pts
1,200 d1, 8,
15 q 4 wks
1.9 0 G3: neutropenia (3), thrombocytopenia (1),
nausea/vomiting (3), cutaneous (2), AST (3),
ALT (5);
G4: neutropenia (1)
Resp eval = Response evaluable; TTP = time to progression; ORR = overall response rate; WHO = World Health Organization;
pts = patients; RD = response duration; G = grade; NA = not available.
a Toxicities reported were grade 63 hepatic (transaminases only), cutaneous, nausea/vomiting, alopecia, neutropenia, and thrombocytopenia,
and all grade 4 toxicities.
b Median TTP based on a personal communication from J. Carmichael.
ment (57% of patients pretreated with at least three lines
of chemotherapy) and the extensive metastatic disease
(visceral disease in 74% of patients, and at least three
organ systems involved in 57% of patients) may partly
account for this outcome. The fact that patients received a
low number of median cycles (2, range 1–8) may also have
contributed to the lack of efficacy, even though during
infusion, the dose intensity was comparatively adequate
(mean dose/infusion = 942 mg/m2).
While the above-mentioned trials all used a standard
infusion time of 30 min, Schmid et al. [20] extended the
infusion duration to 6 h and reduced the gemcitabine dose
to 250 mg/m2 and the cycle length to 3 weeks. This trial,
performed in variably pretreated patients (0–2+ regi-
194 Oncology 2003;64:191–206 Heinemann
mens) produced an overall response rate of 25% (18% of
patients with 2+ prior regimens) and a median time to
progression of 6.3 months.
As a single agent, gemcitabine is moderately active and
well tolerated as first-line and salvage therapy of ad-
vanced breast cancer. Toxicity generally consists of mild
to moderate myelosuppression with minimal clinical con-
sequences, and minimal nonhematologic toxicity, includ-
ing hepatic and cutaneous toxicity and alopecia. This
tolerability is supported by quality-of-life data that appear
essentially unchanged by gemcitabine therapy, with a
slight improvement in emotional functioning [14].
On the basis of these findings, gemcitabine adequately
fits the expectations of a single agent in the treatment of
metastatic breast cancer, and offers a valuable alternative
to the palliative treatment of this disease.
Gemcitabine plus Anthracyclines
Anthracycline-based combination chemotherapy has
become a standard in the treatment of metastatic breast
cancer. Specifically, the FAC regimen, combining 5-fluo-
rouracil, doxorubicin, and cyclophosphamide, may be
considered a landmark in terms of efficacy in the first-line
setting. In a long-term follow-up of 1,581 patients, this
regimen achieved a response rate of 65%, a complete
response rate of 17%, and a median progression-free sur-
vival of 11.5 months [23].
Doxorubicin’s dose-limiting toxicities are myelosup-
pression, mucositis, and cumulative cardiac toxicity.
When gemcitabine is added to doxorubicin, overlapping
toxicity is specifically expected with regard to myelosup-
pression; however, a weekly instead of a monthly applica-
tion of doxorubicin may reduce toxicity.
First-line chemotherapy with gemcitabine and doxo-
rubicin was studied in a phase II trial conducted by Pe-
rez-Manga et al. [24]. Of the 42 patients enrolled, 13 were
chemonaive and 29 had received prior adjuvant chemo-
therapy, which was anthracycline-based in 8 patients.
Gemcitabine (800 mg/m2) and doxorubicin (25 mg/m2)
were both given on days 1, 8 and 15 of a 4-week cycle. In
6 patients, the gemcitabine dose was escalated from 800
to 1,000 mg/m2. Due to toxicity, only 30 cycles were
applied at the higher dose level, and the study was subse-
quently resumed at the gemcitabine dose of 800 mg/m2.
The overall response rate was 55% (complete response
rate of 7%), with 31% of the patients attaining stable dis-
ease. The median response duration was 12 months.
Apart from notable hematotoxicity, the regimen was well
tolerated, as indicated by a low incidence of patient hos-
pitalization, a reduced need for supportive interventions,
and the absence of World Health Organization (WHO)
grade 3/4 cardiotoxicity. Pharmacokinetic studies indi-
cated that the disposition of both drugs was unchanged
when gemcitabine and doxorubicin were administered
on the same day. These data clearly indicate that the
combination is active, with response rates comparing
favorably to those of anthracycline-based combination
regimens.
Excellent results were obtained when the gemcitabine/
doxorubicin combination was assessed as neoadjuvant
therapy. Gomez et al. [25] administered up to three cycles
of gemcitabine 1,200 mg/m2 and doxorubicin 60 mg/m2,
every 3 weeks, followed by surgery or radiotherapy. The
overall response rate in 39 chemonaive patients was 95%
(complete clinical response rate of 18%). Of the 28
patients who underwent mastectomy because their dis-
ease was considered resectable, 3 patients had no evi-
dence of disease upon microscopic evaluation of the mas-
tectomy specimens.
Epirubicin is considered less toxic than doxorubicin,
which may allow higher doses in combination regimens.
The combination of gemcitabine and epirubicin has been
investigated in two phase I trials that have been continued
in phase II trials. Using a fixed dose of gemcitabine
(1,000 mg/m2), one study established the recommended
dose of epirubicin at 15 mg/m2, with both drugs given on
days 1, 8 and 15 of a 4-week cycle [26]. The other phase I
trial evaluated a 3-week schedule of gemcitabine given on
days 1 and 8 and epirubicin on day 1 [27]. This schedule
appeared to be better tolerated than the 4-week schedule,
as the maximum tolerated dose was not reached at gemci-
tabine 1,500 mg/m2 and epirubicin 75 mg/m2. Thus, a
phase II trial was initiated that applied a 3-week regimen
of gemcitabine 1,500 mg/m2 and epirubicin 90 mg/m2
[28]. A preliminary report of these data in 20 patients
(first-line therapy in 48% of patients) indicated significant
and dose-limiting toxicities that may have contributed to
the lower than expected response rate (33%). Therefore,
the gemcitabine regimen was changed to 1,250 mg/m2 on
days 1 and 4, while the epirubicin regimen and cycle dura-
tion remained the same. Fifteen patients received the
modified regimen. Of the 14 evaluable patients, the over-
all response rate was 60% (updated to 67% at final analy-
sis [unpubl. data]). This regimen was better tolerated than
the initial regimen, with fewer dose reductions, grade 4
toxicities, discontinuations due to adverse events, and
serious adverse events.
Gemcitabine in Advanced and Metastatic
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Gemcitabine plus Taxanes
The taxanes docetaxel and paclitaxel promote the for-
mation of tubulin dimers and stabilize microtubules
against depolymerization, thereby causing growth inhibi-
tion and cell death. The single-agent activities of the tax-
anes are comparable [5] or superior [2] to that of doxoru-
bicin, the gold standard in breast cancer treatment. In
combination therapies, the taxanes have been tested pri-
marily with anthracyclines.
New taxane combinations not based on anthracy-
clines, however, are sought primarily because patients are
increasingly given anthracyclines during adjuvant treat-
ment. Thus, at relapse, patients may have developed
anthracycline resistance, as well as cumulative cardiotox-
icity with repeated applications of anthracyclines. Fur-
thermore, because paclitaxel prolongs doxorubicin clear-
ance from plasma, its combination with an anthracycline
may augment cardiotoxicity.
The rationale for combining gemcitabine with taxanes
is not unequivocally supported by preclinical studies.
Some results obtained after concurrent or sequential
treatment of cell lines with gemcitabine and paclitaxel
indicate less than additive or even antagonistic effects
[29], while other in vitro results indicate at least additive
cytotoxicity [30]. Pharmacologic studies did not reveal
any drug interactions at the level of plasma pharmacoki-
netics [31, 32]; however, paclitaxel appears to increase the
accumulation of gemcitabine’s active drug metabolite,
gemcitabine triphosphate, in mononuclear cells, suggest-
ing that this drug may enhance the cytotoxic effects of
gemcitabine in solid tumors [33].
Apart from the apparent inconsistencies of these data,
the combination of gemcitabine and paclitaxel is clearly
favored on the basis of the different mechanisms of action
of the two agents. Moreover, an indication for this drug
combination may be appropriate in anthracycline-pre-
treated patients, in whom high efficacy is still a treatment
goal.
Gemcitabine plus Docetaxel
The combination of gemcitabine and docetaxel has
been explored using different regimens and under differ-
ent pretreatment conditions (table 2). Single-agent doce-
taxel has produced overall response rates of 40–68% [34,
35] in previously untreated patients and 30–42% in
patients previously exposed to anthracycline chemothera-
py [36]. Although more frequent responses are observed
at the higher doses of docetaxel, its use is often limited by
toxicity. The dominant dose-limiting toxicity of docetaxel
is hematotoxicity (mainly neutropenia), followed by other
side effects, such as diarrhea and fluid retention. Thus,
depending on dose and schedule, significant hematotoxic-
ity may be encountered when gemcitabine is combined
with docetaxel [37, 38].
Two studies assessed gemcitabine plus docetaxel in
chemonaive [39] and predominantly chemonaive [38]
patients using 2- and 4-week regimens, respectively. Pele-
gri et al. [39] applied gemcitabine at 2,500 mg/m2 and
docetaxel at 65 mg/m2, every 14 days. This regimen pro-
duced an overall response rate of 72% and grade 3/4 neu-
tropenia in approximately half of the patients. Kornek et
al. [38] administered lower doses of gemcitabine (1,500
mg/m2) and docetaxel (50 mg/m2) at biweekly intervals;
granulocyte colony-stimulating factor (G-CSF) was ad-
ministered depending on patients’ granulocyte nadirs.
The overall response rate was 64% for the 25 chemonaive
patients and 59% for all 34 evaluable patients. Median
time to progression was 7 months. Hematotoxicity was
generally manageable, presumably because of the use of
G-CSF, although septicemia occurred in 9% of patients.
The combination was also assessed as second- or third-
line therapy after relapse or progression with anthracy-
cline and/or taxane chemotherapy [40–43]. These studies
treated patients with 3-week regimens of gemcitabine at
900 or 1,000 mg/m2 and docetaxel from 75 to 100 mg/m2.
Overall response rates varied from 36 to 72%, with the
highest response rate achieved at the 100-mg/m2 docetax-
el dose without G-CSF prophylaxis [43]. Median times to
progression, reported in three of the four studies, ranged
from 6 to 8 months. Interestingly, the combination pro-
duced partial responses in 4 patients who progressed dur-
ing pretreatment with docetaxel or paclitaxel [41], and
partial and complete responses in 72% of patients who
either attained stable disease or progressed during initial
docetaxel treatment [43].
The highest response rate achieved so far (79%) oc-
curred with a 4-week application of gemcitabine 800 mg/
m2 on days 1, 8 and 15 and docetaxel 100 mg/m2 on day 1
[37]. Most patients were pretreated with anthracyclines in
the adjuvant setting. Responses were durable with nearly
all responders progression-free for more than 6 months.
As growth factor use was avoided in an effort to maintain
dose intensity, the hematotoxicity was significant (97% of
patients with grade 3/4 neutropenia) but manageable.
These studies demonstrate that the combination of
gemcitabine and docetaxel may serve as a potent salvage
regimen after anthracycline and/or taxane pretreatment.
Durable responses of up to 79% in pretreated patients are
achievable. Median times to progression (on the order of
7 months) are consistent across various regimens and
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Table 2. Gemcitabine plus docetaxel
Reference
(first author)
N/Resp
eval
Prior chemotherapy Study dose
mg/m2
Median
TTP
months
ORR, % WHO grade 3 or 4 toxicitya, n or % of patients
Laufman
[37]
39/39 1st-line 7 pts
Adjuvant 30 pts
Both 2 pts
Anthracyclines 33 pts
Gem 800 d1, 8, 15
Doc 100 d1
q 4 wks
NA 79 G3/4: neutropenia (39 neutropenic fever in 3),
mucositis (2);
G3 only: thrombocytopenia (1),
nausea/vomiting (2)
Kornek
[38]
52/34 1st-line 43 pts
2nd-line 9 pts
Gem 1,500 d1, 15
Doc 50 d1, 15
q 4 wks
G-CSF
7 59
(median RD = 5 mos)
1st-line: 64 (16/25)
G3: neutropenia (4);
G4: neutropenia (6);
Mild to moderate (grade NA): alopecia (68%),
nausea/vomiting (35%), skin reactions (35%),
septicemia (9%)
Pelegri
[39]
36/25
(29 toxicity
eval)
1st-line 36 pts
Adjuvant 14 pts
Anthracyclines 10 pts
Gem 2,500 d1
Doc 65 d1
q 2 wks
NA 72 G3: neutropenia (7; febrile 1),
thrombocytopenia (1), liver (2);
G4: neutropenia (6)
Brandi
[40]
37/30 2nd-line 13 pts
63rd-line 17 pts
(all pts failed on,
or relapsed after,
first-line anthra-
cycline-based CT)
Gem 1,000 d1, 8
Doc 80 d8
q 3 wks
6 60
(median RD = 5 mos)
G3/4: neutropenia (33%), thrombocytopenia (4%),
nausea/vomiting (4%);
G2/3: alopecia (93%)
Mavroudis
[41]
52/52 2nd-line 27 pts
63rd-line 25 pts
(all pts failed on,
or relapsed after,
first-line anthra-
cycline-based CT)
Neoadjuvant 6 pts
Adjuvant 23 pts
Taxanes 25 pts
Gem 900 d1, 8
Doc 100 d8
q 3 wks
G-CSF (mandatory)
8 54
(median RD = 3.6 mos)
Prior taxanes: 44
(11/25 pts)
G3: neutropenia (10; neutropenic fever in 4),
thrombocytopenia (9), nausea/vomiting (1);
G4: neutropenia (5), thrombocytopenia (2)
Fountzilas
[42]
40/39 2nd-line 20 pts
Adjuvant 3 pts
Both 16 pts
(all anthracycline-
resistant)
Gem 1,000 d1, 8
Doc 75 d1
q 3 wks
G-CSF
7 36
(median RD = 10.3 mos)
2nd-line: 35 (7/20)
Adjuvant: 33 (1/3)
Both: 38 (6/16)
G3: neutropenia (7; febrile neutropenia 7),
thrombocytopenia (1), nausea/vomiting (3),
alopecia (30), dermatitis (1);
G4: neutropenia (12), thrombocytopenia (1)
Alexopoulos
[43]
36/36 2nd- or 3rd-line
(anthracycline-
containing regimens
plus taxanes in
50% of pts)
Gem 900 d1, 8
Doc 100
(schedule NA)
q 3 wks
NA 72
(median RD = 3.2 mos)
None reported
Resp eval = Response evaluable; TTP = time to progression; ORR = overall response rate; pts = patients; RD = response duration; G = grade;
Gem = gemcitabine; Doc = docetaxel; G-CSF = granulocyte colony-stimulating factor; CT = chemotherapy; NA = not available.
a Toxicities reported were grade 63 hepatic (transaminases only), cutaneous, nausea/vomiting, alopecia, neutropenia, and thrombocytopenia,
and all grade 4 toxicities.
conditions of pretreatment. These results are an improve-
ment over those of single-agent docetaxel, and could
indicate clinical synergism, particularly because patients
responded to gemcitabine/docetaxel even after pretreat-
ment, and in some cases after progressing during docetax-
el treatment. The toxicity of the combination is managea-
ble, with hematotoxicity appearing dependent on the dose
and schedule of the regimen.
Gemcitabine plus Paclitaxel
Single-agent paclitaxel has produced overall response
rates of 32–62% in previously untreated patients [44–46],
and 6–48% in anthracycline-resistant patients [47–49].
The addition of gemcitabine to paclitaxel is especially
interesting because paclitaxel is less hematotoxic than
docetaxel at standard doses for each. Overlapping hema-
totoxicity between gemcitabine and paclitaxel should
therefore be less pronounced. The feasibility of combin-
Gemcitabine in Advanced and Metastatic
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Table 3. Gemcitabine plus paclitaxel
Reference
(first author)
N/Resp
eval
Prior chemotherapy Study dose
mg/m2
Median
TTP
months
ORR, % WHO grade 3 or 4 toxicitya, n or % of patients
Colomer
[50]
43/38
(34 toxicity
eval)
1st-line 43 pts
Adjuvant 24 pts
Gem 2,500 d1
Pac 150 (3 hr) d1
q 2 wks
NA 68 G3: neutropenia (5), thrombocytopenia (2),
nausea (2), vomiting (2 pts),
liver transaminases (2);
G4: neutropenia (6), lymphocytes (2),
leukopenia (3), fever and neutropenia (1)
Delfino
[51]
42/42 1st-line 42 pts
Adjuvant 27 pts
Gem 1,200 d1, 8
Pac 175 (3 h) d1
q 3 wks
NA 55
(median RD = 19 mos)
Leukopenia and thrombocytopenia (6 each),
mucositis (7)
Genot
[52]
40/36 1st-line 40 pts Gem 1,200 d1, 8
Pac 175 (3 h) d1
q 3 wks
7.5 42
(median RD = 11.5 mos)
G4: neutropenia (41 events);
G3: leukopenia (52 events); neutropenia
(24 events)
Sanchez
[53]
44/44 2nd-line 44 pts
Anthracyclines 41 pts
Pac 9 pts
Gem 2,500 d1, 15
Pac 135 (3 h) d1, 15
q 4 wks
7 45 G3/4: hematologic toxicity (15% of cycles)
Murad
[54]
29/29 Second or third
relapse during
anthracycline-
based CT 
Gem 1,000 d1, 8
Pac 175 (3 h) d1
q 3 wks
(initial regimen was Gem
1,000 on d1, 8, 15 with
same Pac dose over
4 weeks. This was changed
to 3 weeks with the day-15
dose dropped after unac-
ceptable toxicity (thrombo-
cytopenia) in the first 5 pts)
NA 55
(median RD = 8 mos)
G3: neutropenia (6% of cycles), thrombo-
cytopenia (5% of cycles), nausea/vomiting
(6% of cycles), alopecia (76% of cycles);
G4: neutropenia (3% of cycles; 2 pts w/fever),
thrombocytopenia (3% of cycles), infection
(3% of cycles)
Resp eval = Response evaluable; TTP = time to progression; ORR = overall response rate; WHO = World Health Organization; pts = patients;
RD = response duration; G = grade; Gem = gemcitabine; Pac = paclitaxel; NA = not available.
a Toxicities reported were grade 63 hepatic (transaminases only), cutaneous, nausea/vomiting, alopecia, neutropenia, and thrombocytopenia,
and all grade 4 toxicities.
ing gemcitabine with paclitaxel has been assessed in che-
monaive and pretreated patients (table 3).
Colomer et al. [50] administered a first-line regimen of
gemcitabine 2,500 mg/m2 and paclitaxel 150 mg/m2 both
given on day 1, every 2 weeks. Most patients completed
adjuvant chemotherapy ^12 months before relapse. The
overall response rate in 38 evaluable patients was 68%.
Hematologic toxicity was mainly limited to neutropenia
(32% of patients), with only one report of neutropenic
fever.
Two additional studies of the combination as first-line
therapy for metastatic disease [51, 52] yielded response
rates of 55 and 42%, respectively, using identical 3-week
regimens of 1,200 mg/m2 gemcitabine and 175 mg/m2
paclitaxel. Responses were durable with median response
durations of about 1 year or better (19 and 11.5 months,
respectively). One study reported a median time to pro-
gression of 7.5 months [52].
Sanchez et al. [53] assessed a 4-week schedule of pacli-
taxel at 135 mg/m2 and gemcitabine at 2,500 mg/m2, with
both drugs delivered on days 1 and 15. Patients were
heavily pretreated for metastatic disease (93% with an-
thracycline-based regimens). An overall response rate of
45% was reached, but about a third of the patients
required growth factors to continue receiving the planned
dosing schedule. The median time to progression was 7
months.
Murad et al. [54] conducted a trial in patients who
relapsed a second or third time after anthracycline-based
chemotherapy. Initially, a 4-week regimen of gemcitabine
at 1,000 mg/m2 and paclitaxel at 175 mg/m2 was given on
day 1 (paclitaxel only), 8 and 15. Severe thrombocytope-
nia was observed in the first 5 patients, necessitating a
change in the treatment schedule from 4 to 3 weeks, with
the day-15 gemcitabine dose withdrawn. In these heavily
pretreated patients, the overall response rate was 55%
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Table 4. Gemcitabine plus vinorelbine
Reference
(first author)
N/Resp
eval
Prior chemotherapy Study dose
mg/m2
Median
TTP, months
ORR, % WHO grade 3 or 4 toxicitya, n or % of patients
Haider
[58]
45/45 1st-line 45 pts
2nd-line 15 pts
(anthracyclines 10 pts)
Gem 1,000 d1,
15, 21
Vin 40 d1, 21
q 4 wks
G-CSF
8.5
1st-line: 9.5
2nd-line: 7
52
(median RD = 8.5 mos)
1st-line 56 (25/45)
2nd-line 40 (6/15)
G3: neutropenia (9), nausea/vomiting (3);
G4: neutropenia (2), leukopenia (1)
Valenza
[59]
29/29 2nd-line 29 pts
Anthracycline/taxane
Adjuvant 25 pts
Gem 1,000 d1,
8, 15
Vin 25 d1, 8
q 4 wks
6.8+
(mean)
48 G3: thrombocytopenia (3)
Stathopoulos
[60]
51/50 2nd-line 51 pts
Anthracycline-based CT
Anthracycline/taxane 25 pts
Gem 1,000 d1 15
Vin 25 d1, 15
q 4 wks
6 54
(median RD = 6 mos)
G3/4: neutropenia (4)
Nicolaides
[61]
31/27 2nd-line 31 pts
Taxane-based CT
Gem 1,000 d1, 8
Vin 30 d1, 8
q 3 wks
3.5 22
(median RD = 6 mos)
G3/4: neutropenia (15), thrombocytopenia (1),
paralytic ileus (1), rash (3)
Mariani
[62]b
31/27 2nd- or 63rd-line
(at least 90% of pts)
Anthracycline- and/or
taxane-based CT
Gem 1,200 d1, 8
Vin 30 d1, 8
q 3 wks
NA 22 G3/4: neutropenia (15), thrombocytopenia (2)
Donadio
[63]
26/23 2nd-line 21 pts
3rd-line 5 pts
Anthracyclines 12 pts
Adjuvant and/or
neoadjuvant 19 pts
Gem 1,000 d1, 8
Vin 25 d1, 8
q 3 wks
NA 39 None reported
Moser
[64]
69/30
(38 tox-
icity
eval)
1st-line 25 pts
2nd-line 13 pts
Anthracycline- and/or
taxane-based CT 11 pts
Gem 1,200 d1, 8
Vin 25 d1, 8
q 3 wks
NA 30 G3/4: neutropenia (7), phlebitis (1)
Gokmen
[65]
26/22 1st-line 6 pts
2nd-line 13 pts
3rd-line 7 pts
Anthracycline refractory or
resistant 96% of pts
Gem 1,200 d1, 8
Vin 30 d1, 8
q 3 wks
5.5 45 G3: thrombocytopenia (4), phlebitis (2);
G4: leukopenia (1)
Resp eval = Response evaluable; TTP = time to progression; ORR = overall response rate; WHO = World Health Organization; CT = chemotherapy;
Gem = gemcitabine; Vin = vinorelbine; G-CSF = granulocyte colony-stimulating factor; RD = response duration; G = grade; pts = patients; NA = not available.
a Toxicities reported were grade 63 hepatic (transaminases only), cutaneous, nausea/vomiting, alopecia, neutropenia, and thrombocytopenia,
and all grade 4 toxicities.
b For this phase I/II study, only phase II data are presented.
with a median duration of response of 8 months. Grade
3/4 neutropenia was reported in 30% of patients, which
was accompanied by neutropenic fever in 14% of pa-
tients.
These results demonstrate that the combination of
gemcitabine and paclitaxel is effective in both chemo-
naive and heavily pretreated patients. High and durable
responses across different regimens are achievable. Toxi-
cities are manageable, with neutropenia being the main
toxicity. The response rate of 55% obtained in anthracy-
cline-pretreated patients [54] may be particularly appre-
ciated in view of the low response rate to single-agent
paclitaxel (16%) observed after doxorubicin failure in a
phase III study [3]. Although preclinical data do not pro-
vide an established basis for synergistic drug interaction,
these clinical data clearly support the use of this combina-
tion.
Gemcitabine plus Vinorelbine
Vinorelbine exerts antitumor activity through destabi-
lization of microtubules. While this drug has shown good
efficacy as first-line treatment (40–60%) [55], activity
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after anthracycline pretreatment has only been moderate
(16%) [56, 57]. Vinorelbine is characterized by a favor-
able profile of side effects, with low rates of nausea and
emesis, and almost no alopecia. The dose-limiting toxicity
of vinorelbine is in the form of noncumulative hemato-
toxicity. The potential of adding gemcitabine to vinorel-
bine, two well-tolerated agents with different mechanisms
of action, has been explored in various phase II studies
(table 4).
Haider et al. [58] conducted the only study that evalu-
ated gemcitabine plus vinorelbine separately as first-line
therapy. In a subgroup of 45 chemonaive patients, a 4-
week regimen of gemcitabine 1,000 mg/m2 and vinorel-
bine 40 mg/m2 together with G-CSF support produced an
overall response rate of 56% and a median time to pro-
gression of 9.5 months. In the remaining 15 patients who
were pretreated with palliative therapy (including anthra-
cyclines in 10 patients), lower values of response rate
(40%) and median time to progression (7 months) were
reported.
Two additional studies that applied 4-week regimens
of gemcitabine plus vinorelbine, but solely as second-line
therapy (after anthracyclines B taxanes), achieved re-
sponse rates of 48 and 54%, respectively [59, 60]. Three-
week regimens using identical schedules but slightly dif-
ferent doses of gemcitabine or vinorelbine as second- or
third-line therapy produced lower response rates of 22%
[61, 62] or 39% [63].
Two studies evaluated 3-week regimens in variably
pretreated patients (0–2 prior regimens) [64, 65]. Prelimi-
nary data reported by Moser et al. [64] in 38 eligible
patients (66% chemonaive), indicated an overall remis-
sion rate of 30% in 30 evaluable patients. Gokmen et al.
[65] used an identical regimen except for a slightly higher
dose of vinorelbine (30 vs. 25 mg/m2). Most patients had
undergone one to two prior chemotherapies, although the
pretreatment pattern was not uniform with the combina-
tion administered as first-line therapy in 23%, as second-
line therapy in 50%, and as third-line therapy in 27% of
patients. Anthracycline resistance was described in 31%
of patients, and anthracycline-refractory disease in 65%
of patients. In these predominantly anthracycline-ex-
posed patients, the combination of gemcitabine and vi-
norelbine achieved a response rate of 45% accompanied
by a median time to progression of 5.5 months.
These studies demonstrate that the combination of
gemcitabine and vinorelbine is active not only as first-line
treatment but also after pretreatment with anthracycline-
or anthracycline/taxane-based regimens. Response rates
of up to 54% in anthracycline-pretreated patients are
achievable. Hematotoxicity, the main toxicity of this
combination, appears manageable and generally does not
require the use of hematopoietic growth factors.
Gemcitabine plus Vindesine
Vindesine is a known spindle toxin, with a mechanism
of action comparable to vinorelbine. While drug applica-
tion every 3 weeks may be considered an advantage of this
agent, neurotoxicity is more pronounced compared to
that of vinorelbine. Cazzaniga et al. [66] conducted a mul-
ticenter phase II trial evaluating a 3-week regimen of gem-
citabine (1,000 mg/m2 on days 1 and 8) combined with
vindesine (3 mg/m2 on day 1). All but 1 of the 42 enrolled
patients had prior first-line therapy (21 had anthracy-
clines with or without taxanes and three had taxanes
only). The overall response rate in 25 evaluable patients
was 32% (all partial responses); 24% of patients reached
stable disease. Grade 3/4 neutropenia was observed in
44% of the patients.
Gemcitabine plus Cisplatin
Until recently, cisplatin did not play a significant role
in breast cancer treatment. In five studies analyzing 119
pretreated patients, a mean response rate of 7% was
observed [67–71]. Despite its low activity as a single agent
in salvage therapy, cisplatin appears to be a viable partner
for combination treatment. In fact, it has been successful-
ly tested together with docetaxel, vinorelbine, anti-HER2/
neu antibody, and recently with gemcitabine (table 5).
Three lines of argument support this combination.
First, breast cancer patients treated with standard regi-
mens in the adjuvant or palliative setting will not have
been exposed to gemcitabine or cisplatin in most cases.
Consequently, the probability of pretreatment-induced
drug resistance to these drugs is low. Second, synergistic
cytotoxicity has been observed in vitro when adequate
repair of cisplatin-induced DNA damage was prevented
by gemcitabine [72]. Third, synergistic interaction be-
tween anti-HER2/neu antibody and cisplatin has been
reported both experimentally and in breast cancer pa-
tients [73]. Therefore, the addition of trastuzumab, an
anti-HER2/neu antibody, to gemcitabine/cisplatin might
form an effective triplet combination, and thus may offer
another treatment option after anthracycline and taxane
pretreatment.
Nagourney et al. [74] first described the in vitro syner-
gism of gemcitabine and cisplatin in patients with breast
cancer. Synergistic cytotoxicity was observed in 73% of
225 tumor probes (68% originating from pretreated pa-
tients). As first-line therapy, the combination of gemcita-
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Table 5. Gemcitabine plus cisplatin
Reference
(first author)
N/Resp
eval
Prior chemotherapy Study dose
mg/m2
Median
TTP, months
ORR, % WHO grade 3 or 4 toxicitya, n or % of patients
Calderillo
Ruiz
[75]
31/31 1st-line 31 pts Gem 1,200 d1, 8
Cis 75 d1
q 3 wks
NA 80 G3/4: neutropenia (20% of cycles), anemia
(3% of cycles), thrombocytopenia (2% of cycles),
nausea/vomiting (17% of cycles)
Nagourney
[76]
30/30 2nd- to 6th-line
Anthracyclines 14 pts
Taxanes 20 pts
Gem 1,000 Cis 30
d1, 8, 15 q 4 wks
(after 12 pts,
regimen changed
to Gem 750, Cis 30
d1, 8 q 3 wks)
3.5
2nd- or 3rd-line: 5.5
14th-line: 3.5
50 G3: leukopenia (17% of cycles), neutropenia
(11% of cycles), anemia (6% of cycles),
thrombocytopenia (33% of cycles);
G4: leukopenia (2% of cycles), neutropenia
(4% of cycles), thrombocytopenia (14% of cycles)
Chaudry
[77]
28/28 2nd-line 28 pts
Anthracycline- and
taxane-based CT
Gem 1,000 d1, 8, 15
Cis 25 d1, 8, 15
q 4 wks
NA 39
median RD
= 5.3 mos
G4: thrombocytopenia (12% of cycles),
neutropenia (9% of cycles), nausea/vomiting
(4.5% of cycles)
Burch
[78]
21/21 2nd-line 21 pts
3rd-line 17 pts
Anthracycline or taxane
Gem 1,000 d1, 8, 15
Cis 25 d1, 8, 15
q 4 wks
7.1 29 G3: neutropenia (38%), thrombocytopenia (24%);
G4: neutropenia (43%), thrombocytopenia (38%)
Doroshow
[79]
55/44 M: 24 pts (21 eval)
1st-line, 10 pts;
2nd-line 14 pts
H: 31 pts (23 eval)
13rd-line (including
doxorubicin or a taxane)
Gem 1,000 d2, 8
Cis 25 d1–4
q 3 wks
G-CSF
(mandatory for H)
1st-line 8.3 mos
2nd-line 3.7 mos
13rd-line 3.5 mos
34
M 43
H 26
G3: neutropenia (9), thrombocytopenia (19),
vomiting (8);
G4: neutropenia (30), thrombocytopenia (19),
anemia (5)
Galvez
[80]
41/41 2nd-line 41 pts
Anthracycline-based CT
Gem 1,200 d1, 8, 15
Cis 50 d1
q 4 wks
5.2 49
median RD
= 10.6 mos
G3/4: thrombocytopenia (47%), neutropenia
(48%), anemia (42%), nausea/vomiting (17%),
alopecia (77%), nephrotoxicity (9%), neuropathy
(11%)
Resp eval = Response evaluable; TTP = time to progression; ORR = overall response rate; WHO = World Health Organization;
CT = chemotherapy; RD = response duration; G = grade; pts = patients; Gem = gemcitabine; Cis = cisplatin; NA = not available;
M = moderately pretreated; H = heavily pretreated.
a Toxicities reported were grade 63 hepatic (transaminases only), cutaneous, nausea/vomiting, alopecia, neutropenia,
and thrombocytopenia, and all grade 4 toxicities.
bine (1,200 mg/m2) and cisplatin (75 mg/m2) given every
3 weeks with cisplatin given once during the cycle (day 1)
has proven to be highly effective, reaching a response rate
of 80% in one phase II study [75]. Five additional studies
performed in moderate to intensively pretreated patients,
which used lower doses of cisplatin given repeatedly [76–
79] or once [80] during 3- or 4-week cycles, demonstrated
a median overall response rate of 39% (range 29–50%).
The toxicity profiles of these regimens were moderate,
with thrombocytopenia and neutropenia being the main
side effects.
At present, an optimal regimen for the treatment of
breast cancer has not been determined in a comparative
fashion. To optimize synergy, it was suggested to adminis-
ter ‘repeating doublets’ of drugs [81] such as the applica-
tion used in the Nagourney regimen [76], in which both
drugs were given on days 1 and 8. The efficacy as well as
the hematotoxicity of this drug application appear favor-
able. If outpatient use is preferred, the lower weekly cis-
platin dose (30 mg/m2) that can be applied in these regi-
mens offers an additional advantage.
Gemcitabine plus Epirubicin/Paclitaxel (GET) or
Doxorubicin/Paclitaxel (GAT)
Anthracyclines and the taxanes belong to the most
active groups of agents used in breast cancer treatment. In
principle, there is no evidence that the addition of a third
agent to a doublet truly adds to efficacy more than it adds
to toxicity. A major goal of the combined application of
GET or GAT was to improve the complete response rate,
since it was claimed that patients achieving a complete
response to first-line treatment may be good candidates
for long-term survival [23]. To date, the GET and GAT
trials have been performed exclusively in the first-line set-
ting.
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Two phase II studies evaluating GET have been re-
ported [82, 83]. Both studies used identical 3-week regi-
mens of gemcitabine at 1,000 mg/m2 on days 1 and 4, epi-
rubicin at 90 mg/m2 on day 1, and paclitaxel 175 mg/m2
(3-hour infusion) on day 1. A single-institution study by
Conte et al. [82] showed that this regimen was highly
active, demonstrating an overall response rate of 92% and
a complete response rate of 31% after six courses. Addi-
tionally, 25 of the 36 enrolled patients received high-dose
chemotherapy, providing a final overall response rate of
97% and a complete response rate of 47%. Median time to
progression was 21 months (median follow-up 25
months). On the basis of these very optimistic data, GET
was subsequently tested in a multicenter setting of 39
patients [83]. After a median of two courses, the overall
response rate was 58%, with a complete response rate of
10%. Final response data, after a median of six courses,
are not available. The favorable response rates in these
two studies were accompanied by considerable hemato-
toxicity, with WHO grade 3 and 4 neutropenia reported
in 64 and 59% of the patients, respectively.
Sanchez-Rovira et al. [84] observed an overall re-
sponse rate of 83% (complete response rate of 44%) in a
single-institution study of the GAT combination adminis-
tered to 34 patients over a 4-week schedule (day-2 gemci-
tabine 2,500 mg/m2 and paclitaxel 135 mg/m2, day-1 dox-
orubicin 30 mg/m2). The median duration of response
and the median time to progression were each 14 months.
As with GET, this regimen appears highly active but at
the expense of toxicity, with 21% of cycles reduced or
delayed primarily due to neutropenia, despite the use of
G-CSF in 66% of patients.
As a follow-up to this study, Sanchez-Rovira et al. [85,
86] are also conducting a phase II study of the GAT regi-
men as neoadjuvant therapy in patients with stage II/III
invasive breast cancer. Patients received six cycles of
GAT prior to surgery and three additional cycles after sur-
gery. An overall response rate of 98% (complete response
rate of 42%) has been achieved in 33 assessable patients.
The median duration of response was 13+ months.
Gemcitabine plus 5-Fluorouracil/Leucovorin
The combination of the two antimetabolites, gemcita-
bine and 5-fluorouracil, has shown synergistic cytotoxici-
ty in colorectal tumor cell lines in vitro [87]. Meanwhile,
much knowledge regarding this combination in pancreat-
ic cancer has been accumulated. While toxicity has been
generally moderate, it is unclear whether this drug combi-
nation is superior to that of single-agent gemcitabine.
The approach of combining gemcitabine and 5-fluo-
rouracil in breast cancer is primarily based on the good
tolerability and efficacy of both drugs in this tumor entity.
Thus far, one study of the gemcitabine/5-fluorouracil/leu-
covorin combination has been conducted. Mulkerin et al.
[88] administered gemcitabine 1,000 mg/m2, 5-fluoroura-
cil 600 mg/m2, and leucovorin 20 mg/m2 over 4-week
cycles with all drugs given on days 1, 8 and 15. Most
patients were pretreated with adjuvant and/or metastatic
chemotherapy. This regimen was only moderately active,
producing an overall response rate of 22% in 27 evaluable
patients. Leukopenia was the predominant toxicity. Con-
sidering that gemcitabine treatment alone achieved re-
sponse rates of up to 42% in pretreated patients (table 1),
there is presently no indication that the addition of 5-
fluorouracil improves efficacy.
Gemcitabine plus 5-Fluorouracil/Leucovorin and
Cyclophosphamide
In the phase I portion of a phase I/II study, gemcita-
bine (1,000 mg/m2) was combined with 5-fluorouracil
(425 mg/m2), folinic acid (100 mg/m2), and escalating
doses of cyclophosphamide [89]. All drugs were applied
on days 1 and 8 of a 3-week cycle. The subsequent phase II
portion used a cyclophosphamide dose of 800 mg/m2 sup-
ported by G-CSF. In 21 evaluable patients refractory to
anthracycline- and taxane-based chemotherapy, an over-
all response rate of 43% and a WHO grade 3/4 neutrope-
nia rate of 34% were reported.
Gemcitabine plus a Biologic Agent: Trastuzumab
Gemcitabine has also been combined with paclitaxel
plus the biologic agent trastuzumab as first-line therapy
for patients with newly diagnosed HER2/neu-overex-
pressing metastatic breast cancer. In preclinical studies,
trastuzumab was found to have additive [90] to synergis-
tic [91] effects with some chemotherapeutic agents in
tumor cell lines. Clinical trials in HER2-positive breast
cancer patients have demonstrated that trastuzumab
combined with cytotoxic chemotherapy is associated with
improved time to disease progression and overall survival
[92].
In a first-line study conducted by the Hossier Oncology
Group (HOG) [93], 27 patients (target enrollment of 46)
received a triplet regimen consisting of paclitaxel 175 mg/
m2 over 3 h on day 1, gemcitabine 1,200 mg/m2 on days 1
and 8, and trastuzumab at a 4-mg/kg loading dose on day
1 followed by 2 mg/kg/week, every 21 days. A partial
response was achieved in 92% of 13 evaluable patients,
and only 1 patient has progressed. The treatment has been
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Table 6. Phase III studies planned or in progress: Gemcitabine/taxane combinations in metastatic breast cancer
Location or
cooperative group
Population Approximate
number
Regimens (doses in mg/m2, all 21-day cycles)
Global First-line
Prior adjuvant (anthracycline)
500 Gem 1,250 d1 plus Pac 175 d1
vs. Pac 175 d1
Danish Breast Cancer
Cooperative Group
First- or second-line
(prior anthracycline)
300 Gem 1,000 d1, 8 plus Doc 75 d8
vs. Doc 100 d1
Finnish Cooperative Group First-line 240 Gem 1,000 d1, 8 alternating with Doc 100 d1
vs. Doc 100 d1
United Statesa First- or second-line
(prior anthracycline)
440 Gem 1,000 d1, 8 plus Doc 75 d1
vs. Doc 75 d1 plus Cap 2,000 or 2,500 d1–14
United States Second-line
(prior anthracycline)
210 Gem 1,000 d1, 8 plus Doc 75 d1
vs. Gem 1,000 d1, 8 plus Vin 25 d1, 8
Asia/Pacific First- or second-line
(prior anthracycline)
210 Gem 1,250 d1, 8 plus Pac 175 d1
vs. Gem 1,000 d1, 8 plus Pac 100 d1, 8
vs. Gem 1,000 d1, 8 plus Doc 40 d1, 8
Gem = Gemcitabine; Pac = paclitaxel; Doc = docetaxel; Cap = capecitabine; Vin = vinorelbine.
a A similar study is also being conducted in the European Union.
well tolerated, with grade 4 toxicity limited to myelosup-
pression.
O’Shaughnessy et al. [94] are conducting a phase II
study of gemcitabine 1,200 mg/m2 (days 1 and 8) com-
bined with trastuzumab as a 4-mg/kg loading dose, fol-
lowed by 2 mg/kg/week thereafter, in 55 heavily pre-
treated patients with HER2-positive metastatic breast
cancer. Cycles were administered every 21 days. Among
the 38 assessable patients, 12 had partial responses, for an
overall response rate of 32; 40 (6/15) and 26% (6/23) of
responders were HER2 ++ and +++, respectively. Median
time to progression was 6.7 months. The primary grade
3/4 toxicity was neutropenia, which occurred in 9 pa-
tients.
Future Directions
Due to increasing anthracycline resistance and the risk
of cumulative cardiotoxicity associated with anthracy-
lines, the development of non-anthracycline-containing
regimens in the treatment of metastatic breast cancer is
clearly needed. As a single agent, gemcitabine (1) is active
and well tolerated even as salvage therapy, (2) can be easi-
ly combined with other agents without the confounding
effects of cross-resistance and overlapping toxicity, and
(3) has shown synergistic potential with various cytotox-
ic as well as biologic agents. Thus, phase III trials are
planned or under way to confirm the increased efficacy and
manageable toxicity of gemcitabine when added to non-
anthracycline agents with proven single-agent activity.
On the basis of phase II study results, combinations of
gemcitabine with taxanes appear to offer the most favor-
able balance between efficacy and tolerability. These regi-
mens, particularly the two-drug combinations, have dem-
onstrated durable, high response rates and consistent me-
dian times to disease progression under various pretreat-
ment conditions, without significantly compromising to-
lerability. Various phase III studies are planned or in pro-
gress to establish the role of gemcitabine in combination
with a taxane as first-line or salvage therapy (table 6).
In a large randomized trial by the Central European
Cooperative Oncology Group comparing the GET regi-
men to the triplet combination of 5-fluorouracil/epirubi-
cin/cyclophosphamide (FEC) [95], the clinical value of
the triple-agent approach is being tested as first-line che-
motherapy. An interim analysis of toxicity performed on
22 patients has demonstrated that the administration of
the GET regimen is unproblematic in the multicenter set-
ting; the need for G-CSF support is rare. Neutropenia
grade 3/4 was comparable in the GET and FEC arms (63
vs. 69%, respectively).
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Thus far, GET and GAT trials have been performed
exclusively in the first-line setting, and have yielded high
response rates, perhaps at the expense of acceptable
hematotoxicity. The potential of these dose-dense combi-
nations as conditioning regimens for high-dose chemo-
therapy and/or stem cell support should be affirmed in
phase III trials.
Summary and Conclusion
The rationale for gemcitabine-based combination
treatment is supported by its unique mechanism of ac-
tion, which makes drug resistance to standard pretreat-
ment improbable, and its potential for synergistic drug
interactions. Numerous trials have demonstrated activity
of gemcitabine in the treatment of breast cancer. Gemci-
tabine has proven activity as a well-tolerated single agent
and even as salvage therapy in intensively pretreated
patients. It may be useful in patients who choose pallia-
tion without many side effects, particularly as its use is
not precluded by cumulative organ toxicity. Its combina-
tion with cytotoxic agents such as doxorubicin, the tax-
anes, vinorelbine, vindesine, or cisplatin, and targeted
therapy such as trastuzumab, provides feasible options
with added activity.
Specifically, gemcitabine combinations provide new
options in anthracycline- and taxane-pretreated patients.
Gemcitabine plus taxane regimens appear to offer the
most favorable balance between efficacy and tolerability.
Various confirmatory phase III trials including gemcita-
bine/taxane combinations are planned or in progress. In
addition, single-agent gemcitabine is being studied as
alternating therapy with taxanes in the first-line setting
and also with targeted agents.
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